| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:1928.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
From Weill Medical College of Cornell University, New York, NY (J.N.B., V.P., M.J.R., J.E.L., R.B.D.); Aberdeen Area Tribal Chairmens Health Board, Rapid City, SD (T.K.W.); the University of Oklahoma School of Public Health Services, Oklahoma City (E.T.L.); the Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, Bethesda, Md (R.R.F.); and Medstar Research Institute, Washington, DC (B.V.H.).
Correspondence to Jonathan N. Bella, MD, Division of Cardiology (12th Floor), Bronx-Lebanon Hospital Center/Albert Einstein College of Medicine, 1650 Grand Concourse, Bronx, NY 10457. E-mail jonnbella{at}earthlink.net
| Abstract |
|---|
|
|
|---|
Methods and Results Doppler echocardiograms were analyzed in 3008 American Indian participants in the second Strong Heart Study examination who had no more than mild mitral or aortic regurgitation. Participants were followed for a mean of 3 years after Doppler echocardiography to assess risks of all-cause and cardiac death associated with E/A <0.6 or >1.5; 2429 (81%) participants had normal E/A ratio, 490 (16%) had E/A <0.6, and 89 (3%) had E/A >1.5. All-cause mortality was higher with E/A <0.6 or E/A >1.5 (12% and 13% versus 6%), as was cardiac mortality (4.5% and 6.5% versus 1.6%; both P<0.001). Adjusting for age, sex, body mass index, systolic blood pressure, HDL and LDL cholesterol, smoking, hypertension, diabetes, coronary heart disease, left ventricular hypertrophy, and low ejection fraction (<40%), the relative risk of all-cause death with E/A >1.5 was 1.73 (95% CI, 0.99 to 3.03; P=0.05); the relative risk of cardiac death was 2.8 (95% CI, 1.19 to 6.75; P<0.05). E/A <0.6 was not independently associated with increased all-cause or cardiac mortality (P=0.19 and 0.31, respectively) after adjusting for covariates.
Conclusions In a population-based sample of middle-aged and elderly adults, mitral E/A >1.5 at baseline Doppler echocardiography is associated with 2-fold increased all-cause and 3-fold increased cardiac mortality independent of covariates; mitral E/A <0.6 was also associated with 2-fold increased all-cause and cardiac mortality but not independent of covariates.
Key Words: epidemiology mortality echocardiography diastole aging
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
140 mm Hg systolic and/or 90 mm Hg diastolic or they took antihypertensive medications. Definite or possible coronary heart disease (CHD) was diagnosed on the basis of clinical and ECG evidence of CHD or myocardial infarction9,10; participants were classified as having congestive heart failure (CHF) as previously described.9,10 For the present analysis, participants with
3+ aortic or mitral regurgitation or heart rate >100 bpm were excluded.
Echocardiographic Methods
Imaging and Doppler echocardiograms were performed in 3501 participants (97%) in the second SHS examination with the use of previously described methods.11 Studies were performed with phased-array echocardiography with M-mode, 2-dimensional, and pulsed, continuous-wave, and color-flow Doppler capabilities.
Correct orientation of planes for imaging and Doppler recordings was verified as previously described.12 LV internal dimension and septal and posterior wall thicknesses were measured at end-diastole and end-systole by American Society of Echocardiography recommendations.13,14 Color-flow Doppler recordings were used to search for aortic and mitral regurgitation, as previously described.15
To facilitate relating measurements of LV diastolic transmitral blood flow velocity to volume flow, the pulsed Doppler sample volume was placed at the middle of the mitral annulus, the diameter of which varies relatively modestly during the cardiac cycle, as opposed to the leaflet tips, where the orifice shows substantial variation through the cardiac cycle. The leading edge of the transmitral Doppler flow pattern was traced to derive the peak of early diastolic and atrial phase LV filling ("E" and "A," respectively), their ratio, the deceleration time of early diastolic LV filling, and the atrial filling fraction. Heart rate was measured simultaneously. E/A ratios <0.6 and >1.5 were considered abnormal, representing the 5th and 95th percentiles of a reference range in 124 SHS participants (mean age, 58 years; 78 women) who had normal BP (mean, 113/69 mm Hg), normal body weight (body mass index [BMI] <25 kg/m2), and no prevalent heart disease and were taking no cardiovascular medications. We have previously derived regression equations to predict the E/A at the leaflet tips by using measurements obtained from the annulus (R=0.82, SEE=0.21, P<0.001).16 Annular E/A <0.6 and >1.5 corresponded to E/A <0.7 and >1.5, respectively, at the leaflet tips.
Calculation of Derived Variables
End-diastolic LV dimensions were used to calculate LV mass by a formula17 that yields values closely correlated with necropsy LV weight and that showed good reproducibility.18 LV mass was considered as an unadjusted variable and after adjusting for height to its allometric relation with LV mass (height2.7)19 and for fat-free mass.20 LV mass/height2.7 partition values of 49.2 g/m2.7 (men) and 46.7 g/m2.7 (women) were used to define LV hypertrophy. Relative wall thickness was calculated as posterior wall thickness/LV internal radius.12 End-diastolic and end-systolic LV volumes calculated by Teichholzs method21 were used to calculate stroke volume and ejection fraction (EF).
Clinical End Points
For survival analyses, observation began on the date of echocardiography, with verified data updated through December 1998. Deaths were identified from sources in each community and through annual follow-up of participants and verified through death certificates and review of medical records; only 7 participants (0.2%) were lost to follow-up. Deaths were classified as cardiac if caused by myocardial infarction and as sudden death from CHD or CHF, as previously described,9,10 by an independent review panel of physicians who were unaware of the echocardiographic findings.
Statistical Analyses
Data were analyzed using SPSS 9.0 (SPSS, Inc) software. Data are presented as mean±SD for continuous variables and proportions for categoric variables. The
2 statistic was used to determine categoric variable differences, whereas the general linear model with Sidaks post hoc test was used to determine continuous variable differences among groups. Cox proportional hazards analyses were used to determine relative risks of all-cause and cardiac death with E/A <0.6 or >1.5, after adjusting for age, sex, BMI, systolic BP, HDL and LDL cholesterol, hypertension, diabetes, current smoking, baseline CHD, LV hypertrophy and low EF (<40%). A 2-tailed P<0.05 indicated statistical significance.
| Results |
|---|
|
|
|---|
|
Participants with low E/A had higher prevalences of hypertension and diabetes than did participants with normal or high E/A, although the difference in prevalence of hypertension between the groups with low versus high E/A was not statistically significant. Baseline CHD was 2-fold higher and 4-fold higher among participants with E/A <0.6 or >1.5 than in those with normal E/A. CHF was twice as prevalent in participants with E/A <0.6 and >8-fold higher in those with E/A >1.5 than in those with normal E/A. The prevalence of mitral regurgitation was nearly 3-fold higher in participants with E/A >1.5 than in those with normal E/A, and was lowest in participants with E/A <0.6. In contrast, aortic regurgitation was nearly twice as prevalent in participants with E/A ratio E/A <0.6 or >1.5 than in those with normal E/A. Hypercholesterolemia status did not differ among groups. Prevalence of current smokers was lower in participants with E/A <0.6 than the other 2 groups.
LV Geometry and Function
Septal and posterior wall thicknesses were higher, whereas LV chamber size was smaller in participants with low E/A than in those with normal or high E/A (Table 2). Although there was no difference in septal or posterior wall thickness between groups with normal or high E/A, LV chamber size was largest in participants with E/A >1.5. Although absolute LV mass was statistically equivalent in the groups with low or normal E/A, LV mass/height2.7 was higher with E/A <0.6. Absolute and indexed LV mass were higher in participants with E/A >1.5 than in those with E/A <0.6. Relative wall thickness was highest in participants with E/A <0.6 and lowest in those with E/A >1.5. As a result, the prevalences of concentric LV remodeling and concentric and eccentric LV hypertrophy were 6.7%, 7.4%, and 25.8%, respectively, among participants with E/A <0.6, compared with 2.2%, 1.7%, and 21.2%, respectively, among those with normal E/A ratio and 1.1%, 0%, and 40.2%, respectively, among those with E/A >1.5 (all P<0.001).
|
Compared with participants with normal or low E/A, those with E/A >1.5 had lower EF. As expected, participants with E/A <0.6 had longer deceleration times and higher atrial filling fractions; those with E/A >1.5 had shorter deceleration times and lower atrial filling fractions.
All-Cause and Cardiac Mortality
All-cause mortality was >2-fold higher in both groups with abnormal E/A compared with those with normal E/A (Figure 1, left). A similar relation was observed between abnormal E/A and likelihood of cardiac death (Figure 1, right). Furthermore, among participants with no history of CHF at baseline, all-cause death rates were 2-fold higher with both E/A <0.6 and E/A >1.5 than with normal E/A (14.5 and 20.2 versus 7.8%; P<0.001). Similarly, cardiac death rates were 2-and 4-fold higher among those with E/A <0.6 and E/A >1.5 than those with normal E/A (5.1% and 11.2% versus 2.1%; P<0.001) in this group.
|
Because most previous data relating E/A ratio were obtained in individuals with reduced EF, mortality rates were analyzed separately among SHS participants with EF <40% or
40%. Among participants with EF <40%, both E/A <0.6 and E/A >1.5 groups had higher all-cause (37.5% and 52.9% versus 30.6%) and cardiac mortality rates (25.0% and 35.3% versus 10.2%; all P<0.05). More significantly, among participants with EF
40%, both E/A <0.6 and E/A >1.5 were associated with 2- to 3-fold higher all-cause (14.0% and 12.5% versus 7.4%) and cardiac mortality rates (4.8% and 5.6% versus 1.9%; all P<0.001).
After adjusting for age, sex, BMI, systolic BP, HDL and LDL cholesterol, the presence of hypertension, diabetes, CHD, current smoking, LV hypertrophy, and low EF, the relative risk of all-cause death for SHS participants with E/A >1.5 was 1.73 (95% CI, 0.99 to 3.03; P=0.05) (Figure 2A). In this model, E/A <0.6 was not independently associated with increased all-cause death (RR=1.23; 95% CI, 0.83 to 1.62; P=0.19). After adjustment for age, sex, BMI, systolic BP, HDL and LDL cholesterol, presence of hypertension, diabetes, CHD, LV hypertrophy, and low EF, the relative risk of cardiac death in participants with E/A >1.5 was 2.8 (95% CI, 1.19 to 6.75; P<0.05) (Figure 2B), with no independent association with E/A <0.6 (RR=1.18; 95% CI, 0.7 to 2.1; P=0.31). Reanalysis with the use of the derived E/A at the leaflet tips did not alter the results (data not shown).
|
| Discussion |
|---|
|
|
|---|
Clinical Correlates of Abnormal E/A Ratio
The association between age and impaired early diastolic relaxation is well described.1,2 In our study, those with E/A <0.6 were older, whereas those with E/A >1.5 were, on average, 10 years younger than those with normal E/A. It is possible that some participants with E/A >1.5 had truly normal diastolic filling. However, only 4% of participants with E/A >1.5 were normotensive, nonobese, nondiabetic, and free of clinical heart disease or LV hypertrophy. This suggests that most of the subjects in the high E/A group had a pseudonormal mitral filling pattern induced by elevated filling pressures. Although it has been reported that abnormal diastolic filling occurs in obese individuals,22 the present study of a population-based sample indicates that E/A <0.6 is associated with lower BMI, a particularly notable finding in view of the high prevalences in SHS participants of hypertension and diabetes, conditions associated with obesity. Additionally, participants with E/A >1.5 have lower BMIs than those with normal E/A or E/A <0.6. Further studies are needed to determine the impact of body composition on LV diastolic filling.
Our study confirms and extends previous observations about the association of hypertension and abnormal diastolic filling.2 In the present study, systolic BP was highest among those with E/A <0.6, and pulse pressure was modestly increased in both groups with abnormal E/A. Diabetes was more prevalent in the group with E/A <0.6, in addition to the expected high prevalence of hypertension.2 Similar to the Cardiovascular Health Study,2 we found associations between prevalent CHD or CHF and abnormal diastolic filling.
Prognosis of Abnormal E/A Ratio
Our study shows that E/A >1.5 is independently associated with decreased survival in this population-based sample of middle-aged and elderly adults. These results extend previous reports of associations between restrictive LV filling and poor outcome in patients with dilated cardiomyopathy5 or acute myocardial infarction.6 Our results identify an
2-fold increase in all-cause mortality and 3-fold increase in cardiac mortality associated with E/A >1.5 at baseline Doppler echocardiography. More importantly, our study indicates that the association of E/A >1.5 with cardiac mortality was present in individuals with no history of CHF and in those with EF
40%, suggesting that elevated filling pressures predispose to worse outcome, even in the absence of symptoms or significant systolic dysfunction. These individuals may benefit from more frequent follow-up and more aggressive treatment of conditions associated with abnormal diastolic filling or elevated LV filling pressures. Moreover, we have shown, for the first time, that increased cardiac death rates associated with E/A >1.5 are independent of traditional cardiac risk factors, including older age, male sex, smoking, HDL and LDL cholesterol, prevalent hypertension, diabetes, LV hypertrophy, and low EF. This is especially noteworthy because of the relatively short follow-up (average, 3 years) of this population-based sample.
We have also shown, for the first time, that E/A <0.6 is associated with higher all-cause and cardiac mortality rates in a population-based sample of middle-aged and elderly adults, indicating that severe relaxation impairment predisposes to worse outcome in older adults. However, after adjusting for covariates that included age and LV hypertrophy, E/A <0.6 was not an independent predictor of all-cause or cardiac death. It has been shown that a progressive decline in E/A ratio is associated with further deterioration in other parameters of LV relaxation, including prolongation of the deceleration and isovolumic relaxation times, marked systolic dominance of pulmonary venous inflow, and higher atrial reversal velocity.23 Thus, an E/A <0.6 indicates severe relaxation impairment. Because severe relaxation abnormalities occur commonly in older individuals with abnormal LV mass and geometry23,24 and who may have other cardiovascular risk factors, it is not surprising that a less striking association with E/A <0.6 was seen after covariate adjustment. However, we have also shown that the associated increased mortality rate with E/A <0.6 was present among those with no history of CHF at time of echocardiography, suggesting that an E/A <0.6 in otherwise healthy older adults may require further screening and intervention.
Clinical Implications
Studies have shown that half of instances of CHF in middle-aged and elderly adults are associated with abnormalities in diastolic function rather than systolic dysfunction.25,26 The fact that the association between abnormal E/A and decreased survival was present even in those with no history of CHF suggests that Doppler echocardiography may help identify older adults predisposed to adverse outcomes. We have recently shown that control of hypertension and regression of cardiac hypertrophy improve LV diastolic filling,27 but the impact of these interventions on survival requires further study.
Study Limitations
The E/A ratio used to assess diastolic filling and predict prognosis in this study was not obtained at the leaflet tips, as recommended by consensus statements,4 and thus may reflect volume flow rather than transvalvular gradients that better approximate interactions between chambers during diastole. To avoid excessive burden to SHS participants, no attempt was made to measure isovolumic relaxation time or assess pulmonary venous profiles. Thus, some individuals with pseudonormal filling pattern may be included in the normal E/A group. Although color flow mitral propagation velocity and tissue Doppler imaging of mitral annulus motion would have been useful to complement our assessment of diastolic filling, these newer modalities were not available at the time of study. The partition values that we used represented the 5th and 95th percentiles of an apparently normal subset of the population with similar age range and thus might not be generalizable beyond American Indian SHS participants.
Conclusions
In a population-based sample of middle-aged and elderly adults, mitral E/A >1.5 at baseline Doppler echocardiography is associated with 2-fold increased all-cause and 3-fold increased cardiac mortality rate independent of covariates; mitral E/A <0.6 was also associated with 2-fold increased all-cause and cardiac mortality rates but not independent of covariates.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received November 16, 2001; revision received February 13, 2002; accepted February 14, 2002.
| References |
|---|
|
|
|---|
2. Gardin JM, Arnold AM, Bild DE, at al. Left ventricular diastolic filling in the elderly: the Cardiovascular Health Study. Am J Cardiol. 1998; 82: 345351.
3. Appleton CR, Hatle LK, Popp RL. Relation of transmitral flow velocity patterns to left ventricular diastolic function: new insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol. 1988; 12: 426440.
4. Rakowski H, Appleton C, Chan K-L, et al. Canadian consensus recommendations for measurement and reporting of diastolic dysfunction by echocardiography: from the investigators of Consensus on Diastolic Dysfunction by Echocardiography. J Am Soc Echocardiogr. 1996; 9: 736760.
5. Ortiz J, Matsumota AY, Ghefter CGM, et al. Prognosis in dilated myocardial disease: influence of diastolic dysfunction and anatomical changes. Echocardiography. 1993; 10: 247253.
6. Oh JK, Ding ZB, Gersh BJ, et al. Restrictive left ventricular diastolic filling identifies patients with heart failure after acute myocardial infarction. J Am Soc Echocardiogr. 1992; 5: 497503.
7. Lee ET, Welty TK, Fabsitz R, et al. The Strong Heart Study: a study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol. 1990; 132: 11411155.
8. World Health Organization. Diabetes Mellitus: a Report of a WHO Study Group. Geneva, Switzerland: World Health Organization; 1985.(WHO publication No. 727.)
9. Lee ET, Cowan LD, Sievers M, et al. All-cause mortality and cardiovascular disease mortality in three American Indian populations, aged 4574 years, 19841988: the Strong Heart Study. Am J Epidemiol. 1998; 147: 9951008.
10. Howard BV, Lee ET, Cowan LD, et al. The rising tide of cardiovascular disease in American Indians: the Strong Heart Study. Circulation. 1999; 99: 23892395.
11. Devereux RB, Roman MJ, de Simone G, et al. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation. 1997; 96: 14161423.
12. Devereux RB, Roman MJ. Evaluation of cardiac and vascular structure by echocardiography and other noninvasive techniques.In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, Treatment. 2nd ed. New York: Raven Press; 1995: 19691985.
13. Sahn DJ, De Maria, Kisslo J, et al. The Committee on M-mode Standardization of the American Society of Echocardiography: recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978; 58: 10721083.
14. Schiller NB, Shah PM, Crawford M, et al. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms: recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989; 2: 358367.
15. Cooper JW, Nanda NC, Philpot EF, et al. Evaluation of valvular regurgitation by color Doppler. J Am Soc Echocardiogr. 1989; 2: 5665.
16. Palmieri V, Bella JN, de Quattro V, et al. Relations of left ventricular filling to systolic chamber and myocardial contractility in hypertensive patients with left ventricular hypertrophy: the PRESERVE Study. Am J Cardiol. 1999; 84: 558562.
17. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison of necropsy findings. Am J Cardiol. 1986; 57: 450458.
18. Palmieri V, Dahlof B, DeQuatro V, et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE Study J Am Coll Cardiol. 1999; 34: 16251632.
19. de Simone G, Devereux RB, Daniels SR, et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995; 25: 10561062.
20. Bella JN, Devereux RB, Roman MJ, et al. Relations of left ventricular mass to fat-free and adipose body mass: the Strong Heart Study. Circulation. 1998; 98: 25382544.
21. Teichholz LE, Kreulen T, Herman MV, et al. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol. 1976; 37: 711.
22. Mureddu G, de Simone G, Greco R, et al. Left ventricular filling pattern in uncomplicated obesity. Am J Cardiol. 1996; 77: 509514.
23. Klein AL, Burstow DJ, Tajik AJ, et al. Effects of age on left ventricular dimensions and filling dynamics in 117 normal persons. Mayo Clin Proc. 1994; 69: 212224.
24. Wachtell K, Smith G, Gerdts E, et al. Left ventricular diastolic filling patterns in patients with hypertension and left ventricular hypertrophy (the LIFE Study). Am J Cardiol. 2000; 85: 466472.
25.
Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients
65 years of age: CHS Research Group Cardiovascular Health Study. Am J Cardiol. 2001; 87: 413419.
26. Devereux RB, Roman MJ, Liu JE, et al. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am J Cardiol. 2000; 86: 10901096.
27. Wachtell K, Bella JN, Rokkedal J, et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Circulation. 2002; 105: 10711076.
This article has been cited by other articles:
![]() |
R. M. Wilson, D. S. De Silva, K. Sato, Y. Izumiya, and F. Sam Effects of Fixed-Dose Isosorbide Dinitrate/Hydralazine on Diastolic Function and Exercise Capacity in Hypertension-Induced Diastolic Heart Failure Hypertension, September 1, 2009; 54(3): 583 - 590. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kuznetsova, L. Herbots, B. Lopez, Y. Jin, T. Richart, L. Thijs, A. Gonzalez, M.-C. Herregods, R. H. Fagard, J. Diez, et al. Prevalence of Left Ventricular Diastolic Dysfunction in a General Population Circ Heart Fail, March 1, 2009; 2(2): 105 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. F. Nagueh, C. P. Appleton, T. C. Gillebert, P. N. Marino, J. K. Oh, O. A. Smiseth, A. D. Waggoner, F. A. Flachskampf, P. A. Pellikka, and A. Evangelisa Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography Eur J Echocardiogr, March 1, 2009; 10(2): 165 - 193. [Full Text] [PDF] |
||||
![]() |
G. Grassi, G. Seravalle, F. Quarti-Trevano, R. Dell'Oro, F. Arenare, D. Spaziani, and G. Mancia Sympathetic and Baroreflex Cardiovascular Control in Hypertension-Related Left Ventricular Dysfunction Hypertension, February 1, 2009; 53(2): 205 - 209. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Mahmood, A. Christie, and R. Matyal Transesophageal Echocardiography and Noncardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2008; 12(4): 265 - 289. [Abstract] [PDF] |
||||
![]() |
H. Von Bibra, M. Diamant, P. G Scheffer, T. Siegmund, and P.-M. Schumm-Draeger Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease Diabetes and Vascular Disease Research, November 1, 2008; 5(4): 310 - 318. [Abstract] [PDF] |
||||
![]() |
C. Jarnert, A. Melcher, K. Caidahl, H. Persson, L. Ryden, and M. J. Eriksson Left atrial velocity vector imaging for the detection and quantification of left ventricular diastolic function in type 2 diabetes Eur J Heart Fail, November 1, 2008; 10(11): 1080 - 1087. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ishizu, Y. Seo, S. Kawano, S. Watanabe, T. Ishimitsu, and K. Aonuma Stratification of impaired relaxation filling patterns by passive leg lifting in patients with preserved left ventricular ejection fraction Eur J Heart Fail, November 1, 2008; 10(11): 1094 - 1101. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Patel, V. J.B. Robinson, R. B. Arteaga, and J. W. Thornton Diastolic Filling Parameters Derived from Myocardial Perfusion Imaging Can Predict Left Ventricular End-Diastolic Pressure at Subsequent Cardiac Catheterization J. Nucl. Med., May 1, 2008; 49(5): 746 - 751. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. de Simone, J. S. Gottdiener, M. Chinali, and M. S. Maurer Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study Eur. Heart J., March 2, 2008; 29(6): 741 - 747. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Siegmund, P.-M. Schumm-Draeger, D. Antoni, and H. Von Bibra Beneficial effects of ramipril on myocardial diastolic function in patients with type 2 diabetes mellitus, normal LV systolic function and without coronary artery disease: a prospective study using tissue Doppler Diabetes and Vascular Disease Research, December 1, 2007; 4(4): 358 - 364. [Abstract] [PDF] |
||||
![]() |
S. M. Bierig, A. Ryan, A. Ziaee, L. Kociolek, J. Simon, S. Herrmann, and A. J. Labovitz Serial changes in systolic and diastolic echocardiographic indices as predictors of outcome in patients with decreased left ventricular ejection fraction Eur J Echocardiogr, October 1, 2007; 8(5): 369 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. H. Gaasch and W. C. Little Assessment of Left Ventricular Diastolic Function and Recognition of Diastolic Heart Failure Circulation, August 7, 2007; 116(6): 591 - 593. [Full Text] [PDF] |
||||
![]() |
J. N. Kirkpatrick, M. A. Vannan, J. Narula, and R. M. Lang Echocardiography in Heart Failure: Applications, Utility, and New Horizons J. Am. Coll. Cardiol., July 31, 2007; 50(5): 381 - 396. [Abstract] [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF] |
||||
![]() |
C. Avgeropoulou, A. Illmann, P.-M. Schumm-Draeger, J. Kallikazaros, and H. Von Bibra Assessment of arterio-ventricular coupling by tissue Doppler and wave intensity in type 2 diabetes The British Journal of Diabetes & Vascular Disease, November 1, 2006; 6(6): 271 - 278. [Abstract] [PDF] |
||||
![]() |
M. Galderisi Diastolic Dysfunction and Diabetic Cardiomyopathy: Evaluation by Doppler Echocardiography J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1548 - 1551. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Eryonucu, N. Guler, U. Guntekin, and M. Tuncer Comparison of the Effects of Nitroglycerin and Nitroprusside on Transmitral Doppler Flow Parameters in Patients with Hypertensive Urgency Ann. Pharmacother., June 1, 2005; 39(6): 997 - 1001. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. W. Nielsen, A. Sajedieh, F. Petersen, and J. Fischer Hansen Value of left ventricular filling parameters to predict mortality and functional class in patients with heart disease from the community Eur J Echocardiogr, March 1, 2005; 6(2): 85 - 91. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Von Bibra, I. S Thrainsdottir, A. Hansen, V. Dounis, K. Malmberg, and L. Ryden Tissue Doppler imaging for the detection and quantitation of myocardial dysfunction in patients with type 2 diabetes mellitus Diabetes and Vascular Disease Research, February 1, 2005; 2(1): 24 - 30. [Abstract] [PDF] |
||||
![]() |
D. J. Campbell, M. Woodward, J. P. Chalmers, S. A. Colman, A. J. Jenkins, B. E. Kemp, B. C. Neal, A. Patel, and S. W. MacMahon Prediction of Heart Failure by Amino Terminal-pro-B-Type Natriuretic Peptide and C-Reactive Protein in Subjects With Cerebrovascular Disease Hypertension, January 1, 2005; 45(1): 69 - 74. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Beinart, V. Boyko, E. Schwammenthal, R. Kuperstein, A. Sagie, H. Hod, S. Matetzky, S. Behar, M. Eldar, and M. S. Feinberg Long-term prognostic significance of left atrial volume in acute myocardial infarction J. Am. Coll. Cardiol., July 21, 2004; 44(2): 327 - 334. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Redfield, R. J. Rodeheffer, S. J. Jacobsen, D. W. Mahoney, K. R. Bailey, and J. C. Burnett Jr Plasma Brain Natriuretic Peptide to Detect Preclinical Ventricular Systolic or Diastolic Dysfunction: A Community-Based Study Circulation, June 29, 2004; 109(25): 3176 - 3181. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. McGavock, S. Mandic, I. Vonder Muhll, R. Z. Lewanczuk, H. A. Quinney, D. A. Taylor, R. C. Welsh, and M. Haykowsky Low Cardiorespiratory Fitness Is Associated With Elevated C-Reactive Protein Levels in Women With Type 2 Diabetes Diabetes Care, February 1, 2004; 27(2): 320 - 325. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nodari, M. Metra, and L. D. Cas {beta}-Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol Eur J Heart Fail, October 1, 2003; 5(5): 621 - 627. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang, G. Azhar, M. C. Furr, Y. Zhong, and J. Y. Wei Model of functional cardiac aging: young adult mice with mild overexpression of serum response factor Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R552 - R560. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Muiesan, M. Lupia, M. Salvetti, C. Grigoletto, N. Sonino, M. Boscaro, E. A. Rosei, F. Mantero, and F. Fallo Left ventricular structural and functional characteristics in Cushing's syndrome J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2275 - 2279. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Liu, D. C. Robbins, V. Palmieri, J. N. Bella, M. J. Roman, R. Fabsitz, B. V. Howard, T. K. Welty, E. T. Lee, and R. B. Devereux Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: The Strong Heart Study J. Am. Coll. Cardiol., June 4, 2003; 41(11): 2022 - 2028. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Peterson, M. R. Rinder, K. B. Schechtman, R. J. Spina, K. L. Glover, D. T. Villareal, and A. A. Ehsani Peak exercise stroke volume: associations with cardiac structure and diastolic function J Appl Physiol, March 1, 2003; 94(3): 1108 - 1114. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Redfield, S. J. Jacobsen, J. C. Burnett Jr, D. W. Mahoney, K. R. Bailey, and R. J. Rodeheffer Burden of Systolic and Diastolic Ventricular Dysfunction in the Community: Appreciating the Scope of the Heart Failure Epidemic JAMA, January 8, 2003; 289(2): 194 - 202. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |